Clinical Trial Detail

NCT ID NCT03922880
Title Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

melanoma

uveal melanoma

Therapies

ADI-PEG 20 + Ipilimumab + Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST